

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

24 November 2025

Life Science REIT plc
(the "Company" or "LABS")
Result of General Meeting and Service of Protective Notice

On 4 November 2025, the Company announced the publication of a circular (the "**Circular**") to convene a general meeting to allow Shareholders to consider and, if thought fit, approve a change to the Company's investment objective and policy in order to implement the recommended proposals for managed wind-down of the Company.

The Board today announces that the ordinary resolution to adopt the New Investment Objective and Investment Policy of the Company has been approved by Shareholders.

Voting results of the General Meeting

The table below sets out the results of the vote at the General Meeting

	<i>Votes For (including discretionary)</i>	<i>Votes Against</i>	<i>Votes Total</i>	<i>Votes Withheld¹</i>
<i>Number of Ordinary Shares</i>	167,215,462	920,924	168,136,386	191,130
<i>% of voted Ordinary Shares</i>	99.45	0.55	100.00	-
<i>% of total voting rights²</i>	47.78	0.26	48.04	-

¹ A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for and against the ordinary resolution

² The number of Ordinary Shares in issue as at the voting record time of 6.30 p.m. (London time) on 20 November 2025 (the "**Voting Record Time**") was 350,000,000. As at that date no Ordinary Shares were held in treasury. Therefore, the total number of voting rights in the Company as at the Voting Record Time was 350,000,000.

Service of Protective Notice

The Board also announces that it served 2 years' protective notice to terminate the investment advisory agreement entered into between the Company, G10 Capital Limited and Ironstone Asset Management Limited, on the earliest date upon which protective notice could have been served.

Unless otherwise defined, all capitalised terms used in this announcement have the meanings given to them in the Circular.

The Company's LEI is 213800RG7JNX7K8F7525.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Life Science REIT plc

Claire Boyle, Chair

via Panmure Liberum

MUFG Corporate Governance Limited - Company Secretary

labs_cosec@cm.mpms.mufg.com

Panmure Liberum - Financial Adviser & Corporate Broker

+44 20 7886 2500

Tom Scrivens / Chris Clarke / Alex Collins / Ashwin Kohli

G10 Capital Limited - AIFM

+44 20 7397 5450

Maria Baldwin

FTI Consulting - PR Adviser

Dido Laurimore / Richard Gotla / Oliver Parsons

+44 20 3727 1000

LifeScienceReit@fticonsulting.com

The person responsible for arranging for the release of this announcement on behalf of the Company is MUFG Corporate Governance Limited.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMFLFEELDLSFIE